{"id":"vifor-and-epo","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombotic events (with EPO)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vifor (ferric carboxymaltose) delivers iron directly to the body to correct iron deficiency, which is essential for hemoglobin synthesis. EPO acts as a hematopoietic agent that binds to erythropoietin receptors on bone marrow progenitor cells, stimulating erythropoiesis and increasing red blood cell count. Together, they address both iron availability and erythrocyte production in anemia management.","oneSentence":"Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:37.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Iron deficiency anemia"},{"name":"Anemia of chronic kidney disease"},{"name":"Anemia associated with chronic disease"}]},"trialDetails":[{"nctId":"NCT02060851","phase":"PHASE4","title":"Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants","status":"COMPLETED","sponsor":"Kunshan First People's Hospital Affiliated to Jiangsu University","startDate":"2014-02","conditions":"Malnutrition","enrollment":96},{"nctId":"NCT02031289","phase":"PHASE4","title":"Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-12","conditions":"Anemia, Iron Deficiency","enrollment":1003}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["iron-supplemented combined EPO group"],"phase":"marketed","status":"active","brandName":"Vifor and EPO","genericName":"Vifor and EPO","companyName":"Kunshan First People's Hospital Affiliated to Jiangsu University","companyId":"kunshan-first-people-s-hospital-affiliated-to-jiangsu-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia. Used for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}